Lives unaffected by cystic fibrosis


Back to the Drug Development Pipeline

Hypertonic Saline

To Patients

To Patients

Therapeutic Approach

Mucociliary Clearance

Hypertonic saline as an inhaled therapy is believed to increase hydration of airway surface liquid in people with CF, thereby improving mucus clearance.


A Phase 3 trial conducted in Australia showed beneficial effects of hypertonic saline on pulmonary health in people with CF ages 6 years and older. A Phase 2 trial of hypertonic saline in preschool children is currently underway.


In The US, the program is fully funded through Cystic Fibrosis Foundation Therapeutics and Facilitated by the Cystic Fibrosis Foundation’s Therapeutics Development Network Coordinating Centre.

Contact us about Hypertonic Saline >